News Breaks |
|
|
| March 11, 2013 |
| 12:28 EDT |  | MDT | Medtronic says study shows no increased safety risk for stent
Medtronic announced that cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute drug-eluting stent from the company as participants in one of several clinical studies and interrupted or discontinued their dual antiplatelet therapy after one month of the implant procedure showed no increased safety risk through one year of follow-up. The finding comes from a new analysis of nearly 5,000 patients from the global RESOLUTE clinical program, which included two large studies that enrolled "all comers," Medtronic said. |
|
|
News For MDT From The Last 14 Days Check below for free stories on MDT the last two weeks. |
|
|
| May 16, 2013 |
| 13:32 EDT |  | MDT | Medtronic volatility flat into Q4 and outlook
 Subscribe for More Information |
|
| 10:03 EDT |  | MDT | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 06:32 EDT | | MDT | Medtronic downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information |
|
| May 10, 2013 |
| 15:49 EDT | | MDT | Medtronic defibrillators demonstrate success of shock avoidance
Subscribe for More Information |
|
| May 8, 2013 |
| 07:38 EDT |  | MDT | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information |
|
| May 6, 2013 |
| 09:19 EDT | | MDT | Medtronic receives FDA approval for newest cardiac devices
Medtronic announced FDA approval and U.S. launch of its newest cardiac devices: the Viva portfolio of cardiac resynchronization therapy with defibrillation, or CRT-D, devices, and the Evera portfolio of implantable cardioverter-defibrillators. |
|
|
|
|
|
